Gleason Group, Inc. Cue Biopharma, Inc. Call Options Transaction History
Gleason Group, Inc.
- $547 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding CUE
# of Institutions
56Shares Held
11.7MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$3.7 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$1.71 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$559,9840.0% of portfolio
-
Geode Capital Management, LLC Boston, MA694KShares$513,4780.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$354,0900.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $26.2M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...